DE10041217A1 - Use of dihydroboswellic acids or hydrogenated extracts from Boswellia for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions - Google Patents

Abstract

The invention relates to dihydroboswellic acids and the physiologically tolerable salts and derivatives thereof, the physiologically tolerable salts of said derivatives and hydrogenated extracts of boswellia. The invention also relates to a method for the production of the same and the use of dihydroboswellic acids, physiologically tolerable salts, and derivatives thereof, the physiologically tolerable salts of said derivatives or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment of undesired physical or mental conditions in humans or animals.

Description

The present invention relates to dihydroboswellic acids and their physio logically acceptable salts, derivatives and salts of derivatives and hydrogenated Boswellia extracts, process for their preparation and their use of dihydroboswellic acids, physiologically acceptable salts, derivatives, Salts of derivatives or hydrogenated extracts from Boswellia for prophylactic purposes and / or therapeutic treatment of undesirable physical or mental states in humans or animals.

Gum resin from Boswellia serrata (Indian frankincense) is because of its aro aromatic fragrance known as a therapeutic agent in aromatherapy. In this It serves in particular to restore the mental context Balance, especially for depression and mood disorders.

From Dt Ärztebl 1998; 95: A-30-31 [Book 1-2] is known to be made of gum resin Boswellia serrata Roxb in India as a traditional medicine from Ayurvedi medicine for a number of inflammatory diseases, such as play rheumatoid arthritis, osteoarthritis and cervical spondylosis becomes. The main components of this gum resin are boswellic acids and other compounds, such as essential oils, terpinols, arabinose, xylose, galak tose, uronic acids, b-sitosterol and phlobaphene. Tablets from extracts This resin is used in India for the treatment of chronic polyarthritis manufactured under the trade names Sallaki® and H15®. Boswellia extracts and Boswellic acids have anti-inflammatory properties, as in one Numerous animal models could be demonstrated. Boswellic acids are  also components of the gum resin from Boswellia carterii Birdw., which in German pharmacopoeias (supplementary volume DAB 6 and DAB 1) as an olibanum was led. The previously known pharmacological effects of Oliba num are considered anti-inflammatory, analgesic, immunosuppressive, hepa described to be protective and antimicrobial. Boswellic acids have been shown that they have similar properties.

Inflammation is characterized by redness, warmth, swelling, pain and impaired organ function. These symptoms are characterized by a number of Inflammatory mediators evoked. The current treatment of Inflammation occurs either through compounds that link the prostaglandin synthesis, but not inhibit leukotriene synthesis; they are considered non-steroidal anti-inflammatory drugs / anti-rheumatic drugs; or by glucocor ticoids that inhibit the formation of prostaglandins and leukotrienes. Both However, categories of these anti-inflammatory drugs come with one whole series of sometimes serious side effects. This applies in particular especially for the chronic use of glucocorticoids.

Prostaglandins and leukotrienes are called arachidonic acid cascade formed. From the above publication is a concentration dependent inhibitory effect of boswellic acids, especially of acetyl Boswellic acids on the formation of leukotrienes and other 5- Lipoxygenase products known. Among the boswellic acids, acetyl 11keto-boswellic acid strongest in vitro (IC50 = 1.5 µM). More subs possible effects of an acetyl-boswellic acid mixture on the Cyclooxygenase or 12-lipoxygenase showed that this is neither the Prostaglandin synthesis still affect the 12-lipoxygenase activity ver would like to. The results indicated that these natural products are within the scope the arachidonic acid cascade only inhibit the formation of leukotrienes. Further studies on this topic showed that it was a non-competi tive and reversible effect on this enzyme.  

In addition to the inhibitory effect on leukotriene biosynthesis, the Above publication described that boswellic acids, however in much higher concentrations, in vitro the proliferation of tumor cells like HL60 and CCRF-CEM inhibit gliobastoma cells and melanoma cell membranes.

In the case of HL60 cells, induction of Apoptosis and inhibition of topoisomerase I were observed.

Leukotrienes have a number of effects, most of which are involved in the inflammatory process. However, there were also broncho constrictive effects described. There are a lot of chronic ones inflammatory diseases in which increased leukotriene production as jointly responsible for the maintenance of chronic inflammation is seen. These diseases include ulcerative colitis, disease Crohn, bronchial asthma, rheumatoid arthritis and others.

From DE-A-42 01 903 and EP-A-0 552 657 the use is purer Boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant-containing boswellic acid Preparation for the prophylaxis and / or the fight against inflammation that are caused by increased leukotriene formation in the Human or veterinary medicine known.

WO 97/07796 describes the use of pure boswellic acid, one physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation for the Pro containing boswellic acid phylaxis and / or fighting diseases caused by increased leu cytocytic elastase or plasma activity are caused or by Treated inhibition of normal leukocyte elastase or plasma activity bar are known in human or veterinary medicine.

The resin from boswellia species, boswellic acid and their derivatives have have a low toxicity, but side effects (gastrointestinal  Complaints, allergic reactions) even when used as intended Use described (Dt Ärztebl 1998; 95: A-30-31 [Issue 1-2]).

The present invention has for its object to provide a substance len, with the greatest possible avoidance of the state of the art Known disadvantages to preventive or therapeutic techniques Treatment of undesirable physical or mental conditions, especially the diseases mentioned above, can be used.

Surprisingly, it was found that dihydroboswellic acids or hydrogenated extracts from Boswellia in a similar prophylactic and / or manner can be used therapeutically, such as the well-known boswellic acids and bos welliaextrakte. This finding was particularly unexpected because the Hydrogenation of the only carbon-carbon double bond in all of them Boswellic acids shared the basic structure of the molecule's spatial structure changed significantly, so that it could not be assumed that the biochemical activity (inhibitory effect) would be retained.

Mutually independent objects of the present invention are therefore Dihydroboswellic acids, physiologically acceptable salts from Dihydroboswel lias acids and hydrogenated extracts from Boswellia.

Another object of the present invention is the use of Dihydroboswellic acids, physiologically acceptable salts of Dihydrobos Wellia acids or hydrogenated extracts from Boswellia for prophylactic and / or therapeutic treatment of unwanted physical or mental states in humans or animals.

In the context of the present invention, “dihydroboswellic acids” are understood to mean compounds of the formulas A and B, in particular with the substituents listed below:
(A):

R = H: 11-keto-β-dihydroboswellic acid
R = acetyl: acetyl-11-keto-β-dihydroboswellic acid
R = formyl: formyl-11-keto-β-dihydroboswellic acid
(B):

R = H: α-dihydroboswellic acid
R = acetyl: acetyl-α-dihydroboswellic acid
R = formyl: formyl-α-dihydroboswellic acid

Sodium, potassium, ammonium or calcium salts can be used as physiologically acceptable salts of dihydroboswellic acid. As a derivative of dihydroboswellic acid, lower alkyl esters obtained by esterifying the carboxyl group with a C ₁ -C ₆ alcohol, preferably the methyl ester, or esters obtained by esterifying the hydroxyl group with a physiologically acceptable carboxylic acid can be used , Preferred derivatives are β-dihydroboswellic acid acetate, β-dihydroboswellic acid formate, β-dihydroboswellic acid methyl ester, acetyl-β-dihydroboswellic acid, acetyl-11-keto-β-dihydroboswellic acid and 11-keto-β-dihydroboswellic acid. Plants that contain boswellic acid (syn .: boswellic acid) and from which extracts can be obtained for subsequent hydrogenation are, for example: Boswellia (serrata, papyrifera, frereana, carteri, thurifera, glabra, bhaw-dajiana, oblongata, socotraria and other representatives this family).

The compounds which can be used according to the invention are by hydrogenation, preferably by catalytic hydrogenation of Boswellia resin or Boswelli aacids (one or different) or physiologically acceptable salts, Derivatives or salts of the derivatives of these acids are available.

Another object of the present invention is therefore a method for Production of dihydroboswellic acids, their physiologically acceptable Salts, derivatives, salts of derivatives or hydrogenated extracts from Boswellia, taking Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or salts of the derivatives of this acid Ren dissolves in a suitable solvent and the dissolved resin or ge dissolved acids, salts, derivatives or salts of the derivatives in the presence of a Hydrogenation catalyst hydrogenated. Suitable solvents are, for example, Alka nols, especially ethanol, and cyclohexane.

The hydrogenation is carried out in a manner known to the person skilled in the art preferably so that the carbon-carbon double bond of Boswellia acidic backbone is selectively hydrogenated.

The hydrogenation can take place under heterogeneous or under homogeneous catalysis fen.

In heterogeneous catalysis, there is a catalyst which is insoluble in the reaction medium sator, on the surface of which by adsorption and desorption Equilibria of the compound to be hydrogenated and the hydrogen actual catalysis is effected. Precious metals are suitable as catalysts like Pt, Pd and Rh or transition metals like Mo, W, Cr, but especially Fe,  Co u. Ni, either individually or in a mixture, or to increase activity and stability on supports such as activated carbon, aluminum oxide or diatomaceous earth introduced. Raney nickel, bonded to activated carbon, can be used in particular Pd, metallic Pt as well as platinum and zinc oxide.

In homogeneous catalysis, there are soluble catalysts in the reaction medium in front. Suitable catalysts for homogeneous catalysis are transition metal Complexes, for example the well-known Wilkinson catalyst [chlorine tris (triphenylphosphine) rhodium].

Preferably, the hydrogenation with supported catalysts in a heterogeneous NEN system made, for. B. in a fixed bed or in a fluidized bed or in the so-called trickle phase.

The hydrogenation conditions can be determined in a known manner by the person skilled in the art can be varied. The hydrogenation temperature can range from about 0 ° C to about 275 ° C, especially in the range of about 80 ° C to about 120 ° C. The Pressure can range from normal pressure up to about 300 bar, preferably in Range from about 150 bar to about 250 bar.

The un to be treated in the context of the use according to the invention Desired physical or mental states are preferably out chooses from somatic, psychosomatic and mental illnesses in humans or animals; especially among inflammatory processes that caused by increased leukotriene formation and especially with inflammatory joint diseases, epidermal lesions (psoriasis), allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or chronic hepatitis.

Further to be treated in the context of the use according to the invention undesirable physical conditions are preferably selected from those caused by increased leukocyte elastase or plasma activity  be or, by inhibition of normal leukocyte elasta se or plasma activity are treatable; especially among pulmonary emphy acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscido se), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, the caused by increased leukocyte elastase activity, and Tu moren as well as tumor metastases, which result from increased plasma activity be called.

The use according to the invention of dihydroboswellic acids, physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts Boswellia is preferably intraperitoneal, oral, buccal, rectal, intra muscular, topical, subcutaneous, inhalative, intra-articular or intravenous.

In particular, the use according to the invention takes the form of a tablet ten, coated tablets, capsules, solutions, emulsions, ointments, creams, inhalations preparations, aerosols or suppositories.

Another object of the present invention is the use of Dihydroboswellic acids, their physiologically acceptable salts, derivatives, Salts of derivatives or hydrogenated extracts from Boswellia for the production a medicinal product for prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals, especially for the treatment of the above conditions and diseases.

The inventive use of dihydroboswellic acids, their physio logically acceptable salts, derivatives, salts of the derivatives or hydrogenated Extracts from Boswellia for the treatment of undesirable conditions or for Manufacturing a drug can be chemically pure along with others Drugs and / or herbal medicines take place. Suitable drug Substances or pharmaceuticals are described in DE-A-42 01 903, which are hereby incorporated in full Scope referred is listed.  

Examples of such chemically pure drugs are:
Broncholytics and anti-asthmatics, sympathomimetics:
Carbuterol-HCl, Clenbuterol-HCl, Fenoterol-HBr, Isoetarin-HCl, Orciprenalin sulfate, Pirbuterol-HCl, Procaterol-HCl, Reproterol-HCl, Sabutamol sulfate, Terbu talinsulfat, Tulobuterol-HCl.

Antipsoriatics, non-steroidal anti-inflammatory drugs:
Salicylic acid and derivatives.

vitamins:
Folic acid, vitamin E, vitamin B12, vitamin A.

Various:
Cadmium sulfide, benzalkonium chloride, sodium bituminosulfonate, ammoidin, allantoin, methotrexate, paraffin, dioxolone, dithranol, fumaric acid, undecylenic acid, polyoxyethylene lauryl ether sulfate, etretinate, zinc oxide, urea, lactic acid.

Nonsteroidal anti-inflammatory drugs:
Pyrazole derivatives:
Azapropazon, Bumadizon, Famprofazon, Mofebutazon, Nifenazon, Oxyphenbu tazon, Phenylbutazon, Pyrazinobutazon.

Acrylic Acetic Acid Derivatives and Indole Derivatives:
Acemetacin, Bufexamac, Diclofenac, Indometacin, Lonazolac, Proglumetacin, Tolmetin.

Anthranilic acid derivatives:
Flufenamic acid, mefenamic acid, niflumic acid.

Arylpropionic acid derivatives:
Carprofen, fenoprofen, fenbufen, fluorobiprofen, ibuprofen, ketoprofen, napro xen, piroxicam, pirprofen, tiaprofenic acid.

oxicams:
tenoxicam

other:
Benzydamine, benfotiamine, chloroquine, hydroxychloroquine, auranofin, (ID- Giukosylthio) gold, aurothiomalate (= gold keratinate), tetrachlorogold (III) acid, D-penicillamine, hyaluronidase, nabumetone, etofenamate, ademetionin, serra prinophilamid, chlorophosphate amide, seraprophosphate, chlorophosphate, chlorophosphate, serophosphate, chlorophosphate, chlorophosphate, seropeptide , Methotrexate, glucosa minsulfate, penicillin, bee venom preparation, sulfur, oxaceprol, orgotein, sulfa salazzin (= salazosulfapyridine).

The dosage and duration of use of those to be used according to the invention Dihydroboswellic acids, physiologically acceptable salts, derivatives, salts of derivatives or hydrogenated extracts from Boswellia and the production of these medicaments are essentially as in DE-A-42 01 903 or WO 97/07796 for non-hydrogenated boswellic acid and its deri vate described. These two disclosures are therefore fully referred to.

Dihydroboswellic acid and hydrogenated extracts from Boswellia have one clearly distinguishable from that of their unhydrogenated starting compounds Smell, but this is as aromatic and pleasant as that of unhydrogenated starting compounds.

Therefore dihydroboswellic acid and hydrogenated extracts from Boswellia are also usable for aromatherapy. They are also because of their pleasant  Odor and its anti-inflammatory effect described above usable as valuable components of cosmetics and personal care products.

Another object of the present invention is therefore the use of dihydroboswellic acids, their physiologically acceptable salts, Deri vaten, salts of derivatives or hydrogenated extracts from Boswellia in or to Manufacture of hand detergents, hand dishwashing detergents, cosmetics or Personal protection products.

Further objects of the present invention are pharmaceuticals, body care agents, cosmetics, hand detergents and hand dishwashing detergents, the Di hydroboswellic acids, their physiologically acceptable salts, derivatives, salts containing derivatives or hydrogenated extracts from Boswellia.

The cosmetics and personal care products according to the invention such as Hair shampoos, hair lotions, foam baths, shower baths, creams, gels, lo ions, alcoholic and aqueous / alcoholic solutions, emulsions, wax / Fat masses, stick preparations, powder or ointments can be used as additives and additives substances mild surfactants, oil bodies, emulsifiers, superfatting agents, pearlescent waxes, consistency agents, thickeners, polymers, silicone compounds, Fats, waxes, stabilizers, biogenic agents, deodorants, antitranspi rantien, anti-dandruff agents, film formers, swelling agents, UV light protection factors, Antioxidants, hydrotropes, preservatives, insect repellents, Contain self-tanners, solubilizers, perfume oils, dyes and the like th.

Typical examples of suitable mild, i.e. H. particularly skin-friendly tensi de are fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, mono- and / or Dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid dew ride, fatty acid glutamates, α-olefin sulfonates, ether carboxylic acids, alkyl oligoglu cosides, fatty acid glucamides, alkylamidobetaines and / or protein fatty acid condensates, the latter preferably based on wheat proteins.  

Suitable oil bodies are, for example, Guerbet alcohols based on Fettalko bring having 6 to 18, preferably 8 to 10 carbon atoms, esters of linea ren C ₆ -C ₂₂ fatty acids with linear C ₆ -C ₂₂ -fatty alcohols, esters of branched C ₆ -C ₁₃ -Carboxylic acids with linear C ₆ -C ₂₂ fatty alcohols, such as. B. Myristylmy ristat, myristyl palmitate, myristyl stearate, Myristylisostearat, myristyl, My ristylbehenat, cetyl, sostearat Myristylerucat cetyl palmitate, cetyl stearate, Cetyli, cetyl oleate, cetyl behenate, Cetylerucat, Stearylmyristat, Stearylpalmi did cat stearylstearate, Stearylisostearat, stearyl, stearyl, Stearyleru, isostearyl , isostearyl palmitate, Isostearylstearat, isostearyl isostearate, Isostearyloleat, isostearyl behenate, Isostearyloleat, oleyl myristate, oleyl palmitate, oleyl stearate, oleyl isostearate, oleyl oleate, Oleylbehenat, oleyl erucate, Behenylmy ristat, behenyl palmitate, behenyl, Behenylisostearat, behenyl oleate, Behe nylbehenat, behenyl erucate, erucyl myristate, erucyl, erucyl, erucyl , Erucyl oleate, erucyl behenate and erucylerucate.

In addition, esters of linear C ₆ -C ₂₂ fatty acids with branched alcohols, in particular 2-ethylhexanol, esters of hydroxycarboxylic acids with linear or branched C ₆ -C ₂₂ fatty alcohols, in particular dioctyl malates, esters of linear and / or branched fatty acids are also suitable Get polyhydric alcohols (such as propylene glycol, dimer diol or trimer triol) and / or Guerbet alcohol, triglycerides based on C ₆ -C ₁₀ fatty acids, liquid mono- / di- / triglyceride mixtures based on C ₆ -C ₁₈ fatty acids , Esters of C ₆ -C ₂₂ fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, esters of C ₂ -C ₁₂ dicarboxylic acids with linear or branched alcohols with 1 to 22 carbon atoms or polyols with 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, vegetable oils, branched primary alcohols, substituted cyclohexanes, linear and branched C ₆ -C ₂₂ fatty alcohol carbonates, Guerbet carbonates, esters of benzoic acid with linear and / or branched C ₆ -C ₂₂ alcohols (e.g. B. Finsolv® TN), linear or ver branched, symmetrical or asymmetrical dialkyl ethers with 6 to 22 carbon atoms per alkyl group, ring opening products of epoxidized fatty acid esters with polyols, silicone oils and / or aliphatic or naphthenic hydrocarbons, such as. B. squalane, squalene or dialkylcyclohexanes.

Examples of suitable emulsifiers are nonionic surfactants from at least one of the following groups:

• 1. Addition products of 2 to 30 moles of ethylene oxide and / or 0 to 5 moles Propylene oxide on linear fatty alcohols with 8 to 22 carbon atoms, on fatty acids with 12 to 22 carbon atoms, on alkylphenols with 8 to 15 carbon atoms in the alkyl group as well as alkylamines with 8 to 22 carbon atoms in the alkyl radical;
• 2. C _12/18 fatty acid _monoesters and diesters of adducts of 1 to 30 moles of ethylene oxide with glycerol;
• 3. Glycerol mono- and diesters and sorbitan mono- and diesters of saturated ten and unsaturated fatty acids with 6 to 22 carbon atoms and their ethylene oxide;
• 4. Alkyl and / or alkenyl mono- and oligoglycosides with 8 to 22 Carbon atoms in the alk (en) yl radical and their ethoxylated analogs;
• 5. Addition products of 15 to 60 moles of ethylene oxide with castor oil and / or hardened castor oil;
• 6. polyol and in particular polyglycerol esters;
• 7. Adducts of 2 to 15 moles of ethylene oxide with castor oil and / or hardened castor oil;
• 8. _{partial esters} based on linear, branched, unsaturated or saturated C _6/22 fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. Methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucoside (e.g. cellulose);
• 9. Mono-, di- and trialkyl phosphates as well as mono-, di- and / or tri-PEG- alkyl phosphates and their salts;
• 10. wool wax alcohols;
• 11. Polysiloxane-polyalkyl-polyether copolymers or corresponding deriva te;  
• 12. Mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol according to DE 11 65 574 PS and / or mixed esters of fatty acids with 6 to 22 Koh lenstoffatomen, methyl glucose and polyols, preferably glycerol or polyglycerol,
• 13. Polyalkylene glycols as well
• 14 glycerol.

The adducts of ethylene oxide and / or propylene oxide with fat alcohols, fatty acids, alkylphenols, glycerol monoesters and diesters and Sorbi Tan mono- and diesters of fatty acids or castor oil are known, in Commercially available products.

These are homolog mixtures whose average degree of alkoxylation corresponds to the ratio of the amounts of ethylene oxide and / or propylene oxide and substrate with which the addition reaction is carried out. C _12/18 fatty acid _monoesters and diesters of adducts of ethylene oxide with glycerol are known from DE 20 24 051 PS as refatting agents for cosmetic preparations.

Alkyl and / or alkenyl mono- and oligoglycosides, their preparation and their Uses are known from the prior art. They are manufactured in particular by reacting glucose or oligosaccharides with primary ren alcohols with 8 to 18 carbon atoms. Regarding the glycoside residue, it applies that so probably monoglycosides in which a cyclic sugar residue is glycosidically attached to the Fatty alcohol is bound, as well as oligomeric glycosides with an oligomerisa tion degree up to preferably about 8 are suitable. The degree of oligomerization is a statistical mean, one for such technical products is based on the usual homolog distribution.

Typical examples of suitable polyglycerol esters are polyglyceryl-2 dipoly hydroxystearate (Dehymuls® PGPH), polyglycerol-3-diisostearate (Lameform®  TGI), polyglyceryl-4 isostearate (Isolan® GI 34), polyglyceryl-3 oleate, dii sostearoyl polyglyceryl-3 diisostearate (Isolan® PDI), polyglyceryl-3 methylglu cose Distearate (Tego Care® 450), Polyglyceryl-3 Beeswax (Cera Bellina®), Polyglyceryl-4 caprate (Polyglycerol caprate T2010 / 90), Polyglyceryl-3 cetyl Ether (Chimexane® NL), Polyglyceryl-3 Distearate (Crertiophor® GS 32) and Polyglyceryl Polyricinoleate (Admul® WOL 1403), Polyglyceryl Dimerate Iso stearates and their mixtures.

Zwitterionic surfactants can also be used as emulsifiers. Zwitterionic surfactants are surface-active compounds that contain at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule. Particularly suitable zwitterionic surfactants are the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the cocoalkyldimethylam monium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the cocoacylaminopropyldimethylammonium glycinate, and 2-alkylmethyl 3-carboxylate 3-hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethyl carboxymethylglycinate. The fatty acid amide derivative known under the CTFA name Cocamidopropyl Betaine is particularly preferred. Suitable emulsifiers are also ampholytic surfactants. Ampholytic surfactants are surface-active compounds which, in addition to a C _8/18 alkyl or acyl group, contain at least one free amino group and at least one -COOH or -SO ₃ H group in the molecule and are capable of forming internal salts. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylamino butter acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids, each with about 8 to 18 carbon atoms in the alkyl group. Particularly preferred ampholytic surfactants are the N-cocoalkyl aminopropionate, the cocoacylaminoethylaminopropiortate and the C _{12/18 acylsarcosine} . In addition to the ampholytic emulsifiers, quaternary emulsifiers are also suitable, those of the ester quat type, preferably methyl-quaternized difatty acid triethanolamine ester salts, being particularly preferred.

Substances such as lanolin and Lecithin and polyethoxylated or acylated lanolin and lecithin derivatives, Polyol fatty acid esters, monoglycerides and fatty acid alkanolamides are used are, the latter also serving as foam stabilizers.

Pearlescent waxes, for example, are: alkylene glycol esters, especially ethylene glycol distearate; Fatty acid alkanolamides, especially coconut fatty acid diethanolamide; Partial glycerides, especially stearic acid monoglyceride; Esters of polyvalent, optionally hydroxy-substituted carboxylic acids with fatty alcohol fetch with 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; Fatty substances such as fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates which have a total of at least 24 carbon atoms, especially lauron and distearyl ether; Fatty acids such as stearic acid, hydroxystea rinic acid or behenic acid, ring opening products of olefin epoxides with 12 to 22 carbon atoms with fatty alcohols with 12 to 22 carbon atoms and / or polyols with 2 to 15 carbon atoms and 2 to 10 hydroxyl groups pen and their mixtures.

The main consistency agents are fatty alcohols or hydroxy fatty alcohols get with 12 to 22 and preferably 16 to 18 carbon atoms and next to it Partial glycerides, fatty acids or hydroxy fatty acids into consideration. Is preferred a combination of these substances with alkyl oligoglucosides and / or fatty acid N- same chain length methylglucamides and / or polyglycerol poly-12- hydroxystearates.

Suitable thickeners are, for example, Aerosil types (hydrophilic Silicas), polysaccharides, especially xanthan gum, guar guar, agar Agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl cellulose, also higher molecular weight polyethylene glycol monoesters and diesters of fatty acids,  Polyacrylates, (e.g. Carbopole® from Goodrich or Synthalene® from Sigma), Polyacrylamides, polyvinyl alcohol and polyvinyl pyrrolidone, surfactants as for for example ethoxylated fatty acid glycerides, esters of fatty acids with polyols such as pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with narrow homolog distribution or alkyl oligoglucosides as well as electrolytes like table salt and ammonium chloride.

Suitable cationic polymers are, for example, cationic cellulose derivatives vate, such as B. a quaternized hydroxyethyl cellulose, which is called Polymer JR 400® available from Amerchol, cationic starch, copo polymers of diallylammonium salts and acrylamides, quaternized vinyl pyrroles don / vinylimidazole polymers such as B. Luviquat® (BASF), condensation product te of polyglycols and amines, quaternized collagen polypeptides, as in for example lauryldimonium hydroxypropyl hydrolyzed collagen (Lame quat®L / Grünau), quaternized wheat polypeptides, polyethyleneimine, cationic Silicone polymers such as e.g. B. amidomethicones, copolymers of adipic acid and Dimethylaminohydroxypropyldiethylenetriamine (Cartaretine® / Sandoz), Copoly mers of acrylic acid with dimethyldiallylammonium chloride (Merquat® 550 / Chemviron), polyaminopolyamides, e.g. B. described in FR 2252840 A. and their crosslinked water-soluble polymers, cationic chitin derivatives such as quaternized chitosan, optionally microcrystalline ver shares, condensation products from dihaloalkylene, such as. B. with dibromobutane Bisdialkylaminen, such as. B. bis-dimethylamino-1,3-propane, cationic guar Gum, such as B. Jaguar® CBS, Jaguar® C-17, Jaguar® C-16 from Cela nese, quaternized ammonium salt polymers, such as. B. Mirapol® A-15, Mirapol® AD-1, Mirapol® AZ-1 from Miranol.

As anionic, zwitterionic, amphoteric and nonionic polymers com Men, for example, vinyl acetate / crotonic acid copolymers, vinyl pyrrole don / vinyl acrylate copolymers, vinyl acetate / butyl maleate / isobornyl acrylate co polymeric, methyl vinyl ether / maleic anhydride copolymers and their esters, uncrosslinked and polyols crosslinked polyacrylic acids, acrylamidopropyltrimethylammonium chloride / acrylate copolymers,  Octylacrylamide / Methylmeth acrylate / tert. Methacrylate / 2-Hydroxyproyl methacrylate Copolymer right, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymers, vinylpyrrolidone / Dimethylaminoethyl methacrylate / vinylcaprolactam terpolymers and given derivatized cellulose ethers and silicones in question.

Suitable silicone compounds are, for example, dimethylpolysiloxanes, Me thylphenylpolysiloxanes, cyclic silicones as well as amino, fatty acid, alcohol, polyether, epoxy, fluorine, glycoside and / or alkyl modified silicone compounds conditions that are both liquid and resinous at room temperature can. Simethicones, which are mixtures, are also suitable gene from dimethicones with an average chain length of 200 to 300 Dimethylsiloxane units and hydrogenated silicates. A detailed An overview of suitable volatile silicones can also be found by Todd et al. in Cosm. Toil. 91, 27 (1976).

Typical examples of fats are glycerides. a. natural Waxes such as B. candelilla wax, carnauba wax, japan wax, espar Topgrass wax, cork wax, guaruma wax, rice-germ oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, walnut, Lanolin (wool wax), pretzel fat, ceresin, ozokerite (earth wax), petrolatum, Paraffin waxes, micro waxes; chemically modified waxes (hard waxes), such as B. Montanester waxes, Sasol waxes, hydrogenated jojoba waxes and synthetic waxes such as B. polyalkylene waxes and polyethylene glycol wax se in question.

Metal salts of fatty acids, such as. B. magnesium, Aluminum and / or zinc stearate or ricinoleate can be used.

Examples of biogenic active ingredients are tocopherol, tocopherol acetate, Tocopherol palmitate, ascorbic acid, deoxyribonucleic acid, retinol, bisabolol, Allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudoceramides,  to understand essential oils, plant extracts and vitamin complexes hen.

Cosmetic deodorants counteract body odors, cover or eliminate them. Body odors arise from exposure from skin bacteria to apocrine sweat, with unpleasant smelling ab construction products are formed. Accordingly, deodorants contain active ingredients substances that act as germ inhibitors, enzyme inhibitors, or odor absorbers Odor maskers act.

As a germ-inhibiting agent, optionally the cosmos according to the invention tics are generally added against gram-positive bacteria effective substances, such as B. 4-hydroxybenzoic acid and its salts and Ester, N- (4-chlorophenyl) -N '- (3,4 dichlorophenyl) urea, 2,4,4'-trichloro-2'- hydroxydiphenyl ether (triclosan), 4-chloro-3,5-dimethylphenol, 2,2'-methylene bis (6-bromo-4-chlorophenol), 3-methyl-4- (1-methylethyl) phenol, 2-benzyl-4- chlorophenol, 3- (4-chlorophenoxy) -1,2-propanediol, 3-iodo-2-propynyl butyl carbamate, Chlorhexidine, 3,4,4'-trichlorocarbonilide (TTC), antibacterial fragrances, Thy mol, thyme oil, eugenol, clove oil, menthol, mint oil, farnesol, phenoxyetha nol, glycerol monolaurate (GML), diglycerol monocaprinate (DMC), salicylic acid-N- alkylamides such as B. salicylic acid-n-octylamide or salicylic acid-n-decylamide.

Enzyme inhibitors can also be added to the cosmetics according to the invention become. Suitable enzyme inhibitors are, for example, esterase inhibitors. These are preferably trialkyl citrates such as trimethyl citrate, Tripropyl citrate, triisopropyl citrate, tributyl citrate and especially triethyl citrate (Hydagen® CAT, Cognis, Düsseldorf / FRG). The substances inhibit the En enzyme activity and thereby reduce odor. Other substances as Suitable esterase inhibitors are sterolsulfates or phosphates, such as lanosterol, cholesterol, campesterol, stigmasterol and Sitosterol sulfate or phosphate, dicarboxylic acids and their esters, as in for example glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester,  Adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid and malonic acid diethyl ester, hydroxycarboxylic acids and their esters as in for example citric acid, malic acid, tartaric acid or tartaric acid diethyl ester, and zinc glycinate.

Substances, the odor-forming compounds, are suitable as odor absorbers can record and largely hold. They lower the partial pressure of the individual components and thus also reduce their spreading speed ness. It is important that perfumes remain unaffected. odor absorbers have no activity against bacteria. They contain, for example as the main ingredient, a complex zinc salt of ricinoleic acid or spe zielle, largely odorless fragrances, which the expert as "Fixateu re "are known, such as extracts from Labdanum or Styrax or certain Abietic acid derivatives.

Fragrance agents or perfume oils act as odor maskers in addition to their function as odor masking the deodorants their respective fragrance to lend.

Mixtures of natural and synthetic are mentioned as perfume oils Perfumes. Natural fragrances are extracts from flowers (lily, lavender, Roses, jasmine, neroli, ylang-ylang), stems and leaves (geranium, pat chouli, petitgrain), fruits (anise, coriander, caraway, juniper), fruit peel (bergamot, lemon, oranges), roots (mace, angelica, celery, Cardamom, Costus, Iris, Calmus), wood (pine, sandal, guaiac, cedar, Rosewood), herbs and grasses (tarragon, lemongrass, sage, thyme), Needles and twigs (spruce, fir, pine, mountain pine), resins and balms (Galbanum, Elemi, Benzoe, Myrrh, Olibanum, Opoponax). Keep coming animal raw materials, such as civet and castoreum. typical synthetic fragrance compounds are products of the ester, ether, Aldehydes, ketones, alcohols and hydrocarbons. fragrance compounds of the ester type are e.g. B. benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate,  Linalyl acetate, dimethylbenzylcarbinylacetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethyl methylphenyl glycinate, allyl cyclohe xyl propionate, styrallyl propionate and benzyl salicylate. The ethers include for example benzyl ethyl ether, to the aldehydes z. B. the linear alkanals with 8th up to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cycla menaldehyde, hydroxycitronellal, lilial and bourgeonal, to the ketones e.g. B. the Jonone, ∝-isomethyl ionone and methyl cedryl ketone, to the alcohols anethole, Citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and Terpineol, the hydrocarbons mainly include the terpenes and Balsams. However, mixtures of different fragrances are preferred used, which together create an appealing fragrance. Also etheri cal oils of lower volatility, mostly used as aroma components are suitable as perfume oils, e.g. B. sage oil, chamomile oil, clove oil, melis Sen oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, Oliban oil, galbanum oil, labolanum oil and lavandin oil. Preferably be Bergamot oil, dihydromyrcenol, lilial, lyral, citronellol, phenylethyl alcohol, α- Hexylcinnamaldehyde, geraniol, benzylacetone, cyclamenaldehyde, linalool, boi sambrene forte, ambroxan, indole, hedione, sandelice, lemon oil, mandari oil, orange oil, allylamyl glycolate, cyclover valley, lavandin oil, muscatel sal Beöl, β-Damascone, Geraniumöl Bourbon, Cyclohexylsalicylat, Vertofix Coeur, Iso-E-Super, Fixolide NP, Evernyl, Iraldein gamma, Phenylacetic acid, Gerany lacetate, benzyl acetate, rose oxide, romilllat, irotyl and floramat alone or in Mixtures used.

Antiperspirants (antiperspirants) reduce sweat formation by influencing the activity of the eccrine sweat glands, and thus counteract armpit wetness and body odor. Aqueous or anhydrous formulations of antiperspirants typically contain the following ingredients:

• a) astringent active ingredients,
• b) oil components,
• c) nonionic emulsifiers,  
• d) co-emulsifiers,
• e) consistency factors,
• f) auxiliaries such. B. thickeners or complexing agents and / or
• g) non-aqueous solvents such. B. ethanol, propylene glycol and / or Glycerol.

Salts of are particularly suitable as astringent antiperspirant active ingredients Aluminum, zirconium or zinc. Such suitable antiperspirant active ingredients are z. B. aluminum chloride, aluminum chlorohydrate, alumini umdichlorohydrate, aluminum sesquichlorohydrate and their complex compounds z. B. with propylene glycol-1,2. Aluminum hydroxyallantoinate, aluminum chloride tartrate, aluminum-zirconium trichlorohydrate, aluminum-zirconium tetrachloro hydrate, aluminum-zirconium pentachlorohydrate and their complex compound dung z. B. with amino acids such as glycine.

In addition, conventional oil-soluble and water-soluble auxiliaries can be present in smaller amounts in antiperspirants. Such oil-soluble aids can e.g. B. be:

• - anti-inflammatory, skin-protecting or fragrant ethereal oils
• - synthetic skin-protecting agents and / or
• - oil-soluble perfume oils.

Usual water-soluble additives are e.g. B. preservatives, water-soluble Fragrances, pH value adjusting agents, e.g. B. buffer mixtures, water-soluble Verdi bulking agents, e.g. B. water-soluble natural or synthetic polymers such as z. B. xanthan gum, hydroxyethyl cellulose, polyvinyl pyrrolidone or high moles kular polyethylene oxides.

Climbazole, octopirox and zinc pyrethione can be used as antidandruff agents be set.  

Common film formers are, for example, chitosan, microcrystalline chi tosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate- Copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, Collagen, hyaluronic acid or its salts and similar compounds.

Montmorillonites, clay minerals, Pemulen and alkyl-modified carbopol types (Goodrich) are used. Further Suitable polymers or swelling agents can be found in the review by R. Lochhead in Cosm. Toil. 108, 95 (1993).

UV light protection factors include, for example, liquid or crystalline organic substances (light protection filters) at room temperature, which are able to absorb ultraviolet rays and absorb the energy in the form of longer-wave radiation, e.g. B. admit heat again. UVB filters can be oil-soluble or water-soluble. As oil-soluble substances such. B. To name:

• 3-benzylidene camphor or 3-benzylidene norcampher and its derivatives, z. B. 3- (4-methylbenzylidene) camphor as described in EP 0693471 B1;
• 4-aminobenzoic acid derivatives, preferably 4-dimethylamino) benzoic acid 2-ethylhexyl ester, 4- (dimethylamino) benzoic acid 2-octyl ester and 4- (di methylamino) benzoesäureamylester;
• Esters of cinnamic acid, preferably 2-ethylhexyl 4-methoxycinnamate, 4-methoxycinnamic acid propyl ester, 4-methoxycinnamic acid isamyl ester 2-cyano- 2-ethylhexyl 3,3-phenylcinnamate (octocrylene);
• Esters of salicylic acid, preferably 2-ethylhexyl salicylic acid, Salicylic acid 4-isopropyl benzyl ester, salicylic acid homomethyl ester;
• - Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzo phenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4- methoxybenzophenone;
• - Esters of benzalmalonic acid, preferably 4-methoxybenzmalonic acid di-2- ethylhexyl ester;  
• - Triazine derivatives, such as. B. 2,4,6-Trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5- triazine and octyl triazone, as described in EP 0818450 A1 or Dioc tyl Butamido Triazone (Uvasorb® HEB);
• Propane-1,3-diones, such as e.g. B. 1- (4-tert-butylphenyl) -3-4'methoxyphenyl) propane 1,3-dione;
• - Ketotricyclo (5.2.1.0) decane derivatives, as described in EP 0694521 B1.

Possible water-soluble substances are:

• - 2-Phenylbenzimidazole-5-sulfonic acid and its alkali, alkaline earth, ammoni um, alkylammonium, alkanolammonium and glucammonium salts;
• - Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4- methoxybenzophenone-5-sulfonic acid and its salts;
• - Sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-Oxo-3- bornylidenemethyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bornylidene) - sulfonic acid and its salts.

Derivatives of benzoylmethane in particular come as typical UV-A filters in question, such as 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) pro pan-1,3-dione, 4-tert-butyl-4'-methoxydibenzoylmethane (Parsol 1789), 1-phenyl- 3- (4'-isopropylphenyl) propane-1,3-dione and enamine compounds, such as be wrote in DE 197 12 033 A1 (BASF). The UV-A and UV-B filters can can of course also be used in mixtures. In addition to the genann Soluble substances also come with insoluble light protection for this purpose pigments, namely finely dispersed metal oxides or salts in question. examples for Suitable metal oxides are in particular zinc oxide and titanium dioxide and in addition Oxides of iron, zirconium, silicon, manganese, aluminum and cerium as well their mixtures. Silicates (talc), barium sulfate or zinc stea can be used as salts advice can be used. The oxides and salts are in the form of the pigments for skin-care and skin-protecting emulsions and decorative cosmetics ver applies. The particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15  and have 30 nm. You can have a spherical shape, it can however, particles are also used that are ellipsoidal or in otherwise have a shape deviating from the spherical shape. The Pigments can also be surface treated, i.e. H. hydrophilized or are hydrophobic. Typical examples are coated titanium dioxide, such as z. B. Titanium dioxide T 805 (Degussa) or Eusolex® T2000 (Merck). As hydrophobic Coating agents come mainly from silicones and especially trialkoxy octylsilane or Simethicone in question. Be in sunscreen before so-called micro or nanopigments used. Preferably micronized zinc oxide is used. Other suitable UV light protection filters are see the overview by P. Finkel in SÖFW-Journal 122, 543 (1996).

In addition to the two aforementioned groups of primary light stabilizers, secondary light stabilizers of the antioxidant type can also be used to interrupt the photochemical reaction chain which is triggered when UV radiation penetrates the skin. Typical examples are amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydroliponic acid), Au rothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, Palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g. Buthio ninsulfoximine, Homocysteinsulfoximin, Butioninsulfone, Penta-, Hexa-, Hep tathioninsulfox imine) in very low tolerable doses (e.g. B. pmol to µmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, Bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, Ubi chinon and Ubiquinol and their derivatives, vitamin C and derivatives ( e.g. Ascor byl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) as well as coniferyl benzoate of benzoin, rutinic acid and their derivatives , α-glycosyl rutin, ferulic acid, furfurylidene glucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, superoxide dismutase, zinc ate (e.g. ZnO, ZnSO ₄ ) selenium and its derivatives (e.g. B. selenium methionine), stilbenes and their derivatives (z. B. stilbene oxide, trans-stilbene oxide) and the derivatives according to the invention suitable (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients.

To improve the flow behavior, hydrotropes such as ethanol, isopropyl alcohol or polyols can also be used. Polyols that come into consideration here preferably have 2 to 15 carbon atoms and at least two hydroxyl groups. The polyols can also contain further functional groups, in particular amino groups, or be modified with nitrogen. Typical examples are

• - glycerol;
• - Alkylene glycols, such as ethylene glycol, diethylene glycol, propy lenglycol, butylene glycol, hexylene glycol and polyethylene glycols with one average molecular weight of 100 to 1,000 daltons;
• - Technical oligoglycerol mixtures with a degree of self-condensation of 1.5 to 10 such as technical diglycerin mixtures with a diglycerin ring holds from 40 to 50% by weight;
• - Methyl compounds, such as in particular trimethylolethane, trimethylolpro pan, trimethylol butane, pentaerythritol and dipentaerythritol;  
• - Lower alkyl glucosides, especially those with 1 to 8 carbons in Alkyl radicals, such as methyl and butyl glucoside;
• - Sugar alcohols with 5 to 12 carbon atoms, such as sorbitol or mannitol,
• - Sugar with 5 to 12 carbon atoms, such as glucose or sucrose;
• - aminosugars such as glucamine;
• - Dialcohol amines, such as diethanolamine or 2-amino-1,3-propanediol.

Suitable preservatives are, for example, phenoxyethanol, formal dehyde solution, parabens, pentanediol or sorbic acid as well as those in Appendix 6, Parts A and B of the Cosmetics Ordinance listed further substance classes. As Insect repellents come in N, N-diethyl-m-toluamide, 1,2-pentanediol or Ethyl butylacetylaminopropionate in question, Di is suitable as a self-tanner hydroxyacetone.

Suitable dyes for cosmetic purposes and supplied let substances be used, such as in the pub "Cosmetic dyes" from the Deutsche For schungsgemeinschaft, Verlag Chemie, Weinheim, 1984, pp. 81-106 together are posed. These dyes are usually used in concentrations of 0.001 to 0.1% by weight, based on the mixture as a whole.

The total proportion of auxiliaries and additives can be 1 to 50, preferably 5 to 40% by weight, based on the composition. The production of the middle can done by usual cold or hot processes; preferably one works using the phase inversion temperature method.

Claims (13)

1. Use of dihydroboswellic acids, the physiologically acceptable ren salts, derivatives, salts of derivatives or hydrogenated extracts from Bos wellia for the prophylactic and / or therapeutic treatment of un desired physical or mental conditions in humans or animals. 2. Use according to claim 1, characterized in that to be acting undesirable physical or mental states selected are among somatic, psychosomatic and mental illnesses in humans or animals. 3. Use according to claim 1 or 2, characterized in that the undesirable physical conditions to be treated are selected under Inflammatory processes, especially among inflammatory processes caused by increased leukotriene formation. 4. Use according to any one of the preceding claims, characterized ge indicates that the conditions to be treated are selected under ent inflammatory joint diseases, epidermal lesions (psoriasis), allergic severe and chronic asthma, endotoxin shock, inflammatory bowel crane diseases (ulcerative colitis, Crohn's disease) or chronic hepatitis. 5. Use according to claim 1 or 2, characterized in that the unwanted physical conditions to be treated by increased Leukocyte elastase or plasma activity are caused or that the undesirable physical conditions to be treated by inhibiting normal leukocyte elastase or plasma activity are treatable. 6. Use according to claim 5, characterized in that to be acting conditions are selected from emphysema, acute breath emergency syndrome, shock lung, cystic fibrosis (cystic fibrosis), chronic  Bronchitis, glomerulonephritis and rheumatoid arthritis caused by increased te leukocyte elastase activity, and tumors and Tu mormetastases caused by increased plasma activity. 7. Use according to any one of the preceding claims, characterized ge indicates that the use intraperitoneally, orally, buccally, rectally, intra muscular, topical, subcutaneous, inhalative, intra-articular or intravenous. 8. Use according to claim 7, characterized in that the use dung in the form of tablets, dragees, capsules, solutions, emulsions, ointments, Creams, inhalation preparations, aerosols or suppositories are carried out. 9. Use of dihydroboswellic acids, the physiologically acceptable ren salts, derivatives, salts of derivatives or hydrogenated extracts from Bos wellia for the manufacture of a medicament for the prophylactic and / or the therapeutic treatment of undesirable physical or mental problems in humans or animals, especially for the treatment of those in the Claims 2 to 6 states mentioned. 10. Use according to claim 9, characterized in that the use dung together with other chemically pure drugs and / or vegetable Chen drugs. 11. Use of dihydroboswellic acids, the physiologically acceptable ren salts, derivatives, salts of derivatives or hydrogenated extracts from Bos wellia in or for the production of hand washing agents, hand dishwashing agents, Cosmetics or personal care products. 12. Dihydroboswellic acids, their physiologically acceptable salts, deriva te, salts of derivatives or hydrogenated extracts from Boswellia.   13. A process for the preparation of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of derivatives or hydrogenated extracts from Boswellia, wherein

• a) Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or salts of the derivatives of these acids in a suitable solvent and dissolves
• b) the dissolved resin or the dissolved acids, salts, derivatives or salts of the derivatives is hydrogenated in the presence of a hydrogenation catalyst.